Efficacy of Extended Adjuvant Therapy with Aromatase Inhibitors in Early Breast Cancer among Common Clinicopathologically-defined Subgroups: A Systematic Review and Meta-analysis

The role of adjuvant endocrine therapy for women with hormone receptor positive early breast cancer is well established [1]. Aromatase inhibitors (AIs) have been shown to improve breast cancer outcomes for postmenopausal women, and their use in this population is a gold standard [1]. The risk of recurrence persists for more than a decade after the initial 5 years of adjuvant hormonal therapy [2]. This suggests a potential benefit from extended endocrine treatment. While extending treatment beyond 5 year of tamoxifen appears beneficial [3], there remains uncertainty regarding the optimal duration of adjuvant AIs treatment.

from # All Medicine by Alexandros G. Sfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2v7fquQ
via IFTTT